3.98

3.38% 0.13

After Hours: 4.05 0.07 +1.76%

Iovance Biotherapeutics Inc (IOVA)

Overview News Price History Option Chain Financials Why IOVA Down? Discussions Forecast Stock Split

Iovance Biotherapeutics Inc stock is traded at $3.98, with a volume of 18.14M. It is up +3.38% in the last 24 hours and up +16.03% over the past month. Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

Previous Close:

$3.85

Open:

$3.82

24h Volume:

18.14M

Relative Volume:

1.17

Market Cap:

$1.78B

Revenue:

$263.44M

Net Income/Loss:

$-390.98M

P/E Ratio:

-3.5504

EPS:

-1.121

Net Cash Flow:

$-336.24M

1W Performance:

+17.75%

1M Performance:

+16.03%

6M Performance:

+119.89%

1Y Performance:

+13.71%

1-Day Range:

$3.80

$4.00

1-Week Range:

$3.27

$4.00

52-Week Range:

$1.6385

$5.63

Iovance Biotherapeutics Inc Stock (IOVA) Company Profile

Name

Iovance Biotherapeutics Inc

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

(650) 260-7120

Address

825 INDUSTRIAL ROAD, SAN CARLOS

Employee

975

Twitter

Next Earnings Date

2026-05-07

Latest SEC Filings

IOVA's Discussions on Twitter

Compare IOVA vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IOVA Iovance Biotherapeutics Inc	3.98	1.72B	263.44M	-390.98M	-336.24M	-1.121
VRTX Vertex Pharmaceuticals Inc	424.36	109.34B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	74.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	50.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	39.78B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.02B	5.36B	287.73M	924.18M	2.5229

Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-25-26	Upgrade	Citizens	Mkt Perform → Mkt Outperform
Jul-15-25	Downgrade	Goldman	Neutral → Sell
May-16-25	Downgrade	UBS	Buy → Neutral
May-12-25	Downgrade	Truist	Buy → Hold
May-09-25	Downgrade	Citizens JMP	Mkt Outperform → Mkt Perform
Oct-24-24	Initiated	UBS	Buy
Jul-29-24	Downgrade	Piper Sandler	Overweight → Neutral
Nov-20-23	Initiated	Goldman	Buy
Sep-18-23	Reiterated	Barclays	Overweight
May-30-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Mar-27-23	Resumed	Wells Fargo	Equal Weight
Jan-27-23	Upgrade	Piper Sandler	Neutral → Overweight
Dec-09-22	Downgrade	Goldman	Buy → Neutral
Oct-31-22	Initiated	Guggenheim	Neutral
Aug-18-22	Resumed	Wells Fargo	Equal Weight
Jan-28-22	Upgrade	Stifel	Hold → Buy
Dec-07-21	Resumed	Cowen	Outperform
Jun-10-21	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform
May-20-21	Downgrade	Piper Sandler	Overweight → Neutral
May-19-21	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
May-19-21	Downgrade	Stifel	Buy → Hold
May-03-21	Initiated	Truist	Buy
Apr-16-21	Initiated	Goldman	Buy
Mar-08-21	Upgrade	H.C. Wainwright	Neutral → Buy
Dec-15-20	Downgrade	H.C. Wainwright	Buy → Neutral
Oct-06-20	Downgrade	Wells Fargo	Overweight → Equal Weight
Apr-22-20	Initiated	Mizuho	Buy
Mar-04-20	Initiated	Barclays	Overweight
Feb-26-20	Reiterated	H.C. Wainwright	Buy
Feb-26-20	Reiterated	Oppenheimer	Outperform
Dec-18-19	Initiated	JMP Securities	Mkt Outperform
Oct-01-19	Initiated	Stifel	Buy
Apr-29-19	Initiated	Piper Jaffray	Overweight
Feb-28-19	Reiterated	Chardan Capital Markets	Buy
Feb-07-19	Initiated	Robert W. Baird	Outperform
Dec-31-18	Resumed	B. Riley FBR	Buy
Jul-06-18	Reiterated	Chardan Capital Markets	Buy
Apr-10-18	Upgrade	B. Riley FBR, Inc.	Neutral → Buy
Mar-13-18	Reiterated	B. Riley FBR, Inc.	Neutral
Feb-23-18	Downgrade	B. Riley FBR, Inc.	Buy → Neutral
Jan-25-18	Reiterated	H.C. Wainwright	Buy
Nov-01-17	Reiterated	B. Riley FBR, Inc.	Buy

View All

Iovance Biotherapeutics Inc Stock (IOVA) Latest News

09:29 AM

Iovance Biotherapeutics Stock Short Interest Falls to 32.69% - Quiver Quantitative

09:29 AM

May 04, 2026

IOVA Stock Rises As Rival’s FDA Setback Lifts Amtagvi - StocksToTrade

May 04, 2026

IOVA Stock Draws Bullish Calls As Rival Stumbles On FDA Setback - timothysykes.com

May 04, 2026

May 03, 2026

Iovance Biotherapeutics stock hits 52-week high at 4.35 USD - Investing.com

May 03, 2026

CM Management LLC Decreases Stock Holdings in Iovance Biotherapeutics, Inc. $IOVA - MarketBeat

May 03, 2026

May 02, 2026

Iovance Biotherapeutics | ARS: Annual Report to Security Holders - Moomoo

May 02, 2026

This Beaten-Down Growth Stock Could Soar 165%, According to Wall Street - AOL.com

May 02, 2026

This Beaten-Down Growth Stock Could Soar 165%, According to Wall Street - The Motley Fool

May 02, 2026

May 01, 2026

IOVA stock slump takes Wall Street, retail by surprise — here’s why - MSN

May 01, 2026

Iovance’s Plan to Lift Authorized Shares to 650 Million Could Be A Game Changer For Iovance Biotherapeutics (IOVA) - Sahm

May 01, 2026

[ARS] IOVANCE BIOTHERAPEUTICS, INC. SEC Filing - Stock Titan

May 01, 2026

MSN Money - MSN

May 01, 2026

IOVA Earnings History & Surprises | EPS & Revenue Results | IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) - ChartMill

May 01, 2026

Apr 30, 2026

Iovance Biotherapeutics senior executive joins cancer research panel to promote flexible innovation in immunotherapy - Traders Union

Apr 30, 2026

Iovance Biotherapeutics (IOVA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance

Apr 30, 2026

Iovance Biotherapeutics (IOVA) to Post Earnings on Thursday - MarketBeat

Apr 30, 2026

Apr 29, 2026

Iovance Share Increase Proposal Weighs Dilution Risk Against TIL Growth Funding - Yahoo Finance

Apr 29, 2026

Apr 28, 2026

Iovance Biotherapeutics | DEFA14A: Others - Moomoo

Apr 28, 2026

Iovance Biotherapeutics | DEF 14A: Definitive information statements - Moomoo

Apr 28, 2026

Iovance (NASDAQ: IOVA) seeks approval to raise authorized common shares to 650M - Stock Titan

Apr 28, 2026

Iovance Biotherapeutics: Buy, Because Short-Term Competitor Is Out (NASDAQ:IOVA) - Seeking Alpha

Apr 28, 2026

Assessing Iovance Biotherapeutics (IOVA) Valuation After Recent Share Price Recovery And Undervalued Narrative - Sahm

Apr 28, 2026

Apr 27, 2026

IOVA shares jump 8% — what’s retail expecting? - MSN

Apr 27, 2026

May 7 at 8:30 ET: Iovance to give Q1 results and updates - Stock Titan

Apr 27, 2026

Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026 - Yahoo Finance

Apr 27, 2026

Apr 26, 2026

After IOVA stock’s best day in 2 years, analyst sees over 300% upside: Here’s why - MSN

Apr 26, 2026

REPL vs IOVA: FDA decision day could test biotech bulls’ conviction on these melanoma plays - MSN

Apr 26, 2026

Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates - MSN

Apr 26, 2026

Apr 25, 2026

Iovance Biotherapeutics (IOVA) down 2.1% since last earnings report: Can it rebound? - MSN

Apr 25, 2026

Apr 24, 2026

Chardan Capital Maintains Iovance Biotherapeutics (IOVA) Buy Recommendation - MSN

Apr 24, 2026

Iovance falls after guidance cut, revenue miss - MSN

Apr 24, 2026

Apr 23, 2026

Will FDA’s RP1 Setback Refocus Iovance Biotherapeutics' (IOVA) Post-Checkpoint Melanoma Narrative? - Sahm

Apr 23, 2026

IOVA Forecast, Price Target & Analyst Ratings | IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) - ChartMill

Apr 23, 2026

Apr 22, 2026

Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 7.4%Here's What Happened - MarketBeat

Apr 22, 2026

IOVA Stock Grinds Lower As Traders Watch Key Support - StocksToTrade

Apr 22, 2026